BrainsWay to Showcase Deep TMS at the 2025 American Psychiatric Association Annual Meeting in Los Angeles

Exhibit Booth Demonstrations and Participation in Expert Master Course Highlight BrainsWay’s Expanding Role in Psychiatric Care

/EIN News/ -- BURLINGTON, Mass. and JERUSALEM, May 01, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, is proud to announce its participation at the American Psychiatric Association (APA) Annual Meeting, taking place May 17–21, 2025, in Los Angeles, California.

As part of the meeting’s educational programming, there will be a full day master course on Sunday, May 18^, 2025, entitled: “Clinical Applications for Psychiatric Practice: Ketamine and TMS.” The course will provide an in-depth look at the integration of novel treatments into clinical psychiatric practice, highlighting practical approaches for improving patient outcomes through evidence-based, interventional psychiatry. It will feature several prominent clinician-researchers discussing innovative therapeutic approaches, including two presenters from BrainsWay, Dr. Richard Bermudes, the Company’s Chief Medical Officer and Dr. Colleen Hanlon, BrainsWay’s Vice President of Medical Affairs.

“The future of mental health care depends on accessible, effective treatments like TMS. I’m honored to contribute to this dialogue at the APA symposium,” said Dr. Bermudes. “This year’s APA Annual Meeting is an important opportunity to connect with practitioners who are reshaping psychiatric care.”

BrainsWay will also be hosting live demonstrations of its Deep Transcranial Magnetic Stimulation (Deep TMS™) system at its exhibit booth, offering a hands-on opportunity to interact with this innovative treatment modality. Deep TMS is FDA-cleared to treat Major Depressive Disorder (MDD), Anxious Depression, Late-Life Depression, Obsessive-Compulsive Disorder (OCD) and Smoking Addiction.

About BrainsWay

BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with operations in Israel and the U.S., BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.

Forward-Looking Statement

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nothing herein shall be construed as advocacy or promotion of any uses outside BrainsWay’s FDA-cleared labeling, including but not to the use of different treatment modalities in combination to treat any mental health conditions. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: inadequacy of financial resources to meet future capital requirements; changes in technology and market requirements; delays or obstacles in launching and/or successfully completing planned studies and clinical trials; failure to obtain approvals by regulatory agencies on the Company’s anticipated timeframe, or at all; inability to retain or attract key employees whose knowledge is essential to the development of Deep TMS products; unforeseen difficulties with Deep TMS products and processes, and/or inability to develop necessary enhancements; unexpected costs related to Deep TMS products; failure to obtain and maintain adequate protection of the Company’s intellectual property, including intellectual property licensed to the Company; the potential for product liability; changes in legislation and applicable rules and regulations; unfavorable market perception and acceptance of Deep TMS technology; inadequate or delays in reimbursement from third-party payers, including insurance companies and Medicare; inability to commercialize Deep TMS, including internationally, by the Company or through third-party distributors; product development by competitors; inability to timely develop and introduce new technologies, products and applications, which could cause the actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements.

Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s filings with the U.S. Securities and Exchange Commission.

Contacts:
BrainsWay:
Ido Marom
Chief Financial Officer
Ido.Marom@BrainsWay.com

Investors:
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com